133 related articles for article (PubMed ID: 37932931)
1. TOX, TWIST1, STAT4, and SATB1 protein expressions in early-stage mycosis fungoides.
Örnek S; Ozekinci S; Ipin T; Kocaturk E
J Cutan Pathol; 2024 Mar; 51(3):232-238. PubMed ID: 37932931
[TBL] [Abstract][Full Text] [Related]
2. Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma.
Mehdi SJ; Moerman-Herzog A; Wong HK
BMC Cancer; 2021 May; 21(1):492. PubMed ID: 33941102
[TBL] [Abstract][Full Text] [Related]
3. Expression of SATB1, MTI/II and Ki-67 in Mycosis Fungoides.
Jankowska-Konsur A; Kobierzycki C; Reich A; Grzegrzolka J; Bieniek A; Dziegiel P
Anticancer Res; 2016 Jan; 36(1):189-97. PubMed ID: 26722043
[TBL] [Abstract][Full Text] [Related]
4. Molecular markers of early-stage mycosis fungoides.
Zhang Y; Wang Y; Yu R; Huang Y; Su M; Xiao C; Martinka M; Dutz JP; Zhang X; Zheng Z; Zhou Y
J Invest Dermatol; 2012 Jun; 132(6):1698-706. PubMed ID: 22377759
[TBL] [Abstract][Full Text] [Related]
5. Thymocyte selection-associated high-mobility group box as a potential diagnostic marker differentiating hypopigmented mycosis fungoides from early vitiligo: A pilot study.
Ibrahim MA; Mohamed A; Soltan MY
Indian J Dermatol Venereol Leprol; 2021; 87(6):819-825. PubMed ID: 31857520
[TBL] [Abstract][Full Text] [Related]
6. TOX expression in different subtypes of cutaneous lymphoma.
Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
[TBL] [Abstract][Full Text] [Related]
7. TOX Outperforms FOXP3, CD4 and GATA3 in Histopathological Diagnosis of Early Mycosis Fungoides.
Ahmed MM; Hegazy AA; Embaby A; Nawwar EM; Hegazy SA; Ibrahim HM; Gobran MA
Turk Patoloji Derg; 2023; 39(1):15-22. PubMed ID: 35642346
[TBL] [Abstract][Full Text] [Related]
8. TOX acts an oncological role in mycosis fungoides.
Yu X; Luo Y; Liu J; Liu Y; Sun Q
PLoS One; 2015; 10(3):e0117479. PubMed ID: 25811617
[TBL] [Abstract][Full Text] [Related]
9. SATB1 in Malignant T Cells.
Fredholm S; Willerslev-Olsen A; Met Ö; Kubat L; Gluud M; Mathiasen SL; Friese C; Blümel E; Petersen DL; Hu T; Nastasi C; Lindahl LM; Buus TB; Krejsgaard T; Wasik MA; Kopp KL; Koralov SB; Persson JL; Bonefeld CM; Geisler C; Woetmann A; Iversen L; Becker JC; Ødum N
J Invest Dermatol; 2018 Aug; 138(8):1805-1815. PubMed ID: 29751003
[TBL] [Abstract][Full Text] [Related]
10. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
11. TOX expression in cutaneous T-cell lymphomas: an adjunctive diagnostic marker that is not tumour specific and not restricted to the CD4(+) CD8(-) phenotype.
Schrader AM; Jansen PM; Willemze R
Br J Dermatol; 2016 Aug; 175(2):382-6. PubMed ID: 26931394
[TBL] [Abstract][Full Text] [Related]
12. Differential SATB1 Expression Reveals Heterogeneity of Cutaneous T-Cell Lymphoma.
Gao Y; Liu F; Sun J; Wen Y; Tu P; Kadin ME; Wang Y
J Invest Dermatol; 2021 Mar; 141(3):607-618.e6. PubMed ID: 32771472
[TBL] [Abstract][Full Text] [Related]
13. Thymocyte selection-associated high mobility group box gene (TOX) is aberrantly over-expressed in mycosis fungoides and correlates with poor prognosis.
Huang Y; Litvinov IV; Wang Y; Su MW; Tu P; Jiang X; Kupper TS; Dutz JP; Sasseville D; Zhou Y
Oncotarget; 2014 Jun; 5(12):4418-25. PubMed ID: 24947046
[TBL] [Abstract][Full Text] [Related]
14. Correlation of SATB1 expression with clinical course of cutaneous T-cell lymphomas.
Grzanka A; Grzanka D; Gagat M; Tadrowski T; Sokołowska-Wojdyło M; Marszałek A; Placek W
Pol J Pathol; 2012 Jun; 63(2):101-5. PubMed ID: 22864778
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of STAT4 at early stages of mycosis fungoides: Coincidence or not?
Olisova OY; Grekova EV; Zaletaev DV; Alekseeva EA
Australas J Dermatol; 2021 Feb; 62(1):e119-e120. PubMed ID: 32808277
[No Abstract] [Full Text] [Related]
16. The Value of Immunohistochemical Expression of TOX, ICOS, and GATA-3 in the Diagnosis of Mycosis Fungoides.
Atwa HA; Abdelrahman DI
Appl Immunohistochem Mol Morphol; 2023 Mar; 31(3):163-171. PubMed ID: 36805367
[TBL] [Abstract][Full Text] [Related]
17. Decoding Early Mycosis Fungoides: Histopathologic and Immunohistochemical Clues.
Kaya Terzi N
Cureus; 2024 Apr; 16(4):e57545. PubMed ID: 38577165
[TBL] [Abstract][Full Text] [Related]
18. [Current possibilities of the differential diagnosis of plaque parapsoriasis and the early stages of mycosis fungoides].
Olisova OY; Grekova EV; Varshavsky VA; Gorenkova LG; Alekseeva EA; Zaletaev DV; Sydikov AA
Arkh Patol; 2019; 81(1):9-17. PubMed ID: 30830099
[TBL] [Abstract][Full Text] [Related]
19. Special AT-rich sequence-binding protein-1 participates in the maintenance of breast cancer stem cells through regulation of the Notch signaling pathway and expression of Snail1 and Twist1.
Sun Z; Zhang C; Zou X; Jiang G; Xu Z; Li W; Xie H
Mol Med Rep; 2015 May; 11(5):3235-542. PubMed ID: 25586771
[TBL] [Abstract][Full Text] [Related]
20. TOX expression and role in CTCL.
McGirt LY; Degesys CA; Johnson VE; Zic JA; Zwerner JP; Eischen CM
J Eur Acad Dermatol Venereol; 2016 Sep; 30(9):1497-502. PubMed ID: 27345620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
